版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領
文檔簡介
顱內(nèi)動脈粥樣硬化狹窄治療
相關RCT試驗三個提前終止的RCT試驗WASIDtheWarfarin–AspirinSymptomaticIntracranialDiseaseSAMMPRISStentingandAggressiveMedicalManagementforPreventingRecurrentstrokeinIntracranialStenosisESASIStheEarlyStent-assistedAngioplastyinSymptomaticIntracranialStenosisRCT-NO.1NEnglJMed,2005;352(13):1305-1316.ComparisonofWarfarinandAspirin
forSymptomaticIntracranialArterialStenosisBackgroundAtheroscleroticintracranialarterialstenosisisanimportantcauseofstroke.Warfariniscommonlyusedinpreferencetoaspirinforthisdisorder,butthesetherapieshavenotbeencomparedinarandomizedtrial.RCT-NO.1TheWarfarin-AspirinSymptornaticIntracranialDiseaseStudy(NEUROLOGY1995;45:1488-1493.)151Patientswith50to99%stenosisofanintracranialarterywereidentifiedbyreviewingtheresultsofconsecutiveangiogramsperformedatparticipatingcentersbetween1985and1991.Figure.GraphshowsKaplan-Meierestimatesofproportionofpatientsremainingfreeofischemicstroke,myocardialinfarction,orsuddendeathinthosetreatedwithwarfarin(uppercurve)oraspirin(lowercurve).Therelativeriskofamajorvasculareventinthosetreatedwithwarfarinwas0.46(95%CI,0.23to0.86)comparedwithpatientstreatedwithaspirin.MethodsWerandomlyassignedpatientswithtransientischemicattackorstrokecausedbyangiographicallyverified50to99percentstenosisofamajorintracranialarterytoreceivewarfarin(targetinternationalnormalizedratio,2.0to3.0)oraspirin(1300mgperday)inadouble-blind,multicenterclinicaltrial.Theprimaryendpointwasischemicstroke,brainhemorrhage,ordeathfromvascularcausesotherthanstroke.RCT-NO.1After569patientshadundergonerandomization,enrollmentwasstoppedbecauseofconcernsaboutthesafetyofthepatientswhohadbeenassignedtoreceivewarfarin.ResultsRCT-NO.1ConclusionsWarfarinwasassociatedwithsignificantlyhigherratesofadverseeventsandprovidednobenefitoveraspirininthistrial.Aspirinshouldbeusedinpreferencetowarfarinforpatientswithintracranialarterialstenosis.RCT-NO.1StentingversusAggressiveMedicalTherapy
forIntracranialArterialStenosisNEnglJMed2011;365(11):993-1003.RCT-NO.2BackgroundAtheroscleroticintracranialarterialstenosisisanimportantcauseofstrokethatisincreasinglybeingtreatedwithpercutaneoustransluminalangioplastyandstenting(PTAS)topreventrecurrentstroke.However,PTAShasnotbeencomparedwithmedicalmanagementinarandomizedtrial.RCT-NO.2MethodsWerandomlyassignedpatientswhohadarecenttransientischemicattackorstrokeattributedtostenosisof70to99%ofthediameterofamajorintracranialarterytoaggressivemedicalmanagementaloneoraggressivemedicalmanagementplusPTASwiththeuseoftheWingspanstentsystem.Theprimaryendpointwasstrokeordeathwithin30daysafterenrollmentorafterarevascularizationprocedureforthequalifyinglesionduringthefollow-upperiodorstrokeintheterritoryofthequalifyingarterybeyond30days.RCT-NO.2此數(shù)據(jù)有問題Currently,themeandurationoffollowup,whichisongoing,is11.9months.ResultsRCT-NO.2ConclusionsInpatientswithintracranialarterialstenosis,aggressivemedicalmanagementwassuperiortoPTASwiththeuseoftheWingspanstentsystem,bothbecausetheriskofearlystrokeafterPTASwashighandbecausetheriskofstrokewithaggressivemedicaltherapyalonewaslowerthanexpected.
RCT-NO.2此數(shù)據(jù)有問題AggressivemedicalmanagementMedicalmanagementisidenticalinthetwogroupsandconsistsofaspirin,atadoseof325mgperday;clopidogrel,atadoseof75mgperdayfor90daysafterenrollment;managementoftheprimaryriskfactors(elevatedsystolicbloodpressureandelevatedlow-densitylipoprotein[LDL]cholesterollevels);andmanagementofsecondaryriskfactors(diabetes,elevatednon–high-densitylipoprotein[non-HDL]cholesterollevels,smoking,excessweight,andinsufficientexercise)withthehelpofalifestylemodificationprogram.RCT-NO.2AspirinplusclopidogrelMATCHCHARISMACUREAggressivemedicalmanagementWithrespecttotheprimaryriskfactors,wetargetedasystolicbloodpressureoflessthan140mmHg(<130mmHginthecaseofpatientswithdiabetes)andanLDLcholesterolleveloflessthan70mgperdeciliter(1.81mmolperliter).Weprovidetheaspirin,clopidogrel,onedrugfromeachmajorclassofantihypertensiveagents,rosuvastatin,andthelifestyleprogramtothestudypatients.RCT-NO.214.7%5.8%3.8%(35%relativeriskreduction)AcomparisonbetweentheSAMMPRISandESASIStrialsClinicalTrialRegistration:CUHK_CCT00116at.hkRCT-NO.3WiththeannouncementofthesafetyconcernandearlyterminationoftheSAMMPRIStrial,theDataSafetyMonitoringBoard(DSMB)ofESASISstudymetonApril28,2011andreviewedthe30-daysafetydata(combinedstrokeanddeath)for77patientsrandomizedasofApril20,2011.InhislettertotheExecutiveCommittee,theChairoftheDSMBcommentedthat‘…Thesafetydataforthemedicalgroupiscomparabletothe6%reportedforthemedicalarmoftheSAMMPRISstudy,whereasthesafetydataforthestentinggroupis
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 農(nóng)機托管合同模板
- 關于子女撫養(yǎng)權合同模板
- 外協(xié)件采購合同模板
- 圍墻合同模板百度
- 小學法治安全教育演講稿5篇
- 國開行借款合同模板
- 公司轉(zhuǎn)讓個合同模板
- 土地出租 出售合同模板
- 臨時勞務合同模板
- 保潔學校合同模板
- 《西游記》整本書閱讀:品讀西游經(jīng)典感悟英雄成長(課件)-【大單元教學】2024-2025學年七年級語文上冊同步備課系列(統(tǒng)編版2024)
- 2024至2030年中國軌道交通運營維護行業(yè)市場全景評估及投資方向研究報告
- 2024-2030年中國家用洗車機行業(yè)市場發(fā)展趨勢與前景展望戰(zhàn)略分析報告
- 十年(2015-2024)高考真題英語分項匯編(全國)專題 12 閱讀理解應用文(教師卷)
- JB-T 9637-2022 汽輪機 總裝技術規(guī)范
- ISO28000:2022供應鏈安全管理體系
- 醫(yī)療質(zhì)量管理工具應用
- 人工智能設計說明書
- 2024年四川省行測筆試試題及答案
- (2024年)全新信息安全課件
- 東北三省三校2024年高三二模(第二次聯(lián)合模擬考試)政治試卷(含標準答案)
評論
0/150
提交評論